Want to see PTHS full AI Analyst Report?
PTHS Stock Chart & Stats
$26.78
$1.67(6.44%)
At close: 4:00 PM EDT
$26.78
$1.67(6.44%)
Day’s Range― - ―
52-Week Range$18.19 - $37.50
Previous Close$27.59
Volume91.43K
Average Volume (3M)70.63K
Market Cap
$83.84M
Enterprise Value$148.57
Total Cash (Recent Filing)$24.56M
Total Debt (Recent Filing)$73.11M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Nov 12, 2026EPS Estimate
-2.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-41.93
Shares Outstanding3,828,469
10 Day Avg. Volume44,086
30 Day Avg. Volume70,628
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.50
Price to Sales (P/S)3.47
P/FCF Ratio-2.57
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$53.40Price Target Upside99.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-10.35
Revenue Forecast (FY)$63.75M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross MarginRapid revenue expansion combined with improving gross margin indicates stronger product adoption and better unit economics as the commercial platform scales. If maintained, this operating leverage can support reinvestment, improve earnings potential, and strengthen the business over the next several quarters.
Commercial Adoption And Market AccessStrong prescription growth, broad payer access, and expanding patient utilization provide evidence that Zelsuvmi is gaining commercial traction beyond initial launch activity. A growing prescriber and coverage base can create a durable foundation for recurring demand and future product launches.
Pipeline And Commercial PlatformThe planned launches of XEPI and Xeglyze give Pelthos additional opportunities to leverage its established sales force, payer relationships, and dermatology presence. Reusing this infrastructure could improve launch efficiency and increase the long-term productivity of commercial investments.
Bears Say
Persistent Operating LossesLarge operating and net losses, together with substantial free-cash-flow consumption, show that commercial growth has not yet translated into self-funding operations. Continued losses can restrict investment flexibility and increase the company’s need for financing while it scales its products.
Negative Equity And Higher DebtThe shift to negative equity alongside sharply higher debt materially weakens financial resilience and reduces flexibility during execution or demand setbacks. Elevated leverage may increase funding dependence and constrain the resources available for launches, commercialization, and other strategic priorities.
Margin Pressure From Costs And RebatesA higher gross-to-net deduction would reduce realized revenue per prescription and make it harder for strong unit growth to translate into proportional net sales. This pressure could delay operating leverage, weigh on gross profitability, and prolong the path toward sustainable cash generation.
Pelthos Therapeutics News
PTHS FAQ
What was Pelthos Therapeutics’s price range in the past 12 months?
Pelthos Therapeutics lowest stock price was $18.19 and its highest was $37.50 in the past 12 months.
What is Pelthos Therapeutics’s market cap?
Pelthos Therapeutics’s market cap is $83.84M.
When is Pelthos Therapeutics’s upcoming earnings report date?
Pelthos Therapeutics’s upcoming earnings report date is Nov 12, 2026 which is in 60 days.
How were Pelthos Therapeutics’s earnings last quarter?
Pelthos Therapeutics released its earnings results on Aug 13, 2026. The company reported -$6.62 earnings per share for the quarter, missing the consensus estimate of -$2.819 by -$3.801.
Is Pelthos Therapeutics overvalued?
According to Wall Street analysts Pelthos Therapeutics’s price is currently Undervalued.
Does Pelthos Therapeutics pay dividends?
Pelthos Therapeutics does not currently pay dividends.
What is Pelthos Therapeutics’s EPS estimate?
Pelthos Therapeutics’s EPS estimate is -2.9.
How many shares outstanding does Pelthos Therapeutics have?
Pelthos Therapeutics has 3,828,469 shares outstanding.
What happened to Pelthos Therapeutics’s price movement after its last earnings report?
Pelthos Therapeutics reported an EPS of -$6.62 in its last earnings report, missing expectations of -$2.819. Following the earnings report the stock price went up 0.138%.
Which hedge fund is a major shareholder of Pelthos Therapeutics?
Currently, no hedge funds are holding shares in PTHS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pelthos Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$53.40 (99.40% Upside)
$53.40 (99.40% Upside)
Blogger Sentiment
Bullish
PTHS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 22.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $999.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.56%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9999.00%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Pelthos Therapeutics
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.
PTHS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive commercial momentum story: strong quarter-over-quarter prescription and revenue growth, meaningful prescriber and coverage expansion, improving adjusted EBITDA, and a clear plan to leverage commercial infrastructure for two upcoming product launches. Notable challenges include an accounting restatement (limited to fair value measurements), higher SG&A driven largely by one-time items, a COGS increase including an API write-off, a decline in working capital, and expected gross-to-net pressure. Overall, the positive operational and commercial developments and improving profitability trends outweigh the listed challenges, though certain financial and manufacturing risks merit monitoring.View all PTHS earnings summariesPTHS Stock 12 Month Forecast
Average Price Target
$53.40
▲(99.40% Upside)
Technical Analysis
Immunic
―
Fortress Biotech
―
Verrica Pharmaceuticals
―
Instil Bio
―
Tevogen Bio Holdings
―